All lobbying filings

Williams and Jensen, PLLC

Williams and Jensen, PLLC filed a Q3 report for Plasma Protein Therapeutics Association on October 20, 2025, reporting $50,000 in lobbying income.

Lobbying for Plasma Protein Therapeutics Association

As filed: WILLIAMS AND JENSEN, PLLC for PLASMA PROTEIN THERAPEUTICS ASSOCIATION.

All filings by Williams and Jensen, PLLC · Everything Plasma Protein Therapeutics Association has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2025

July 1 - Sep 30 · Posted Oct 20, 2025

Income

$50,000

What the client paid this registrant for the period.

Client based in

Maryland

Official filing document

Lobbyists on this filing 5

JEANNE HAGGERTY New on this filing

Previously held: Legislative Correspondent Senator Chuck Grassley and Senate Aging Committee (shared staff), Legislative Aide Senate Finance Committee, Health Policy Coordinator Health Subcommittee Energy and Commerce, Professional Staff Member
ROBERT BUTORA

Previously held: Health Policy Advisor, Senator Bill Cassidy; Senior Health Policy Advisor, Representative Leonard Lance, Health Legislative Assistant, Representative Michael Burgess
CHRISTOPHER E. WILCOX New on this filing

Previously held: LA, Leg Counsel, LD & Counsel, Rep. Arcuri; LD & Counsel, Rep. Demings
KURT SCHRADER Former member of Congress New on this filing

Previously held: Former Member of Congress
LAURA M SIMMONS

Previously held: Advisor, Office of Legislative Affairs, Dept of Homeland Security

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 4

Taxation/Internal Revenue Code

Tax legislation affecting the Orphan Drug Tax Credit and the Research and Development Tax Credit.

Trade (domestic/foreign)

Issues related to pharmaceutical tariffs and related trade agreements.

Medicare/Medicaid

Access and pricing issues for plasma derived products; Orphan Drug Act and therapies for rare diseases. H.R. 1, One Big Beautiful Bill Act implementation, issues related to biopharmaceutical issues. Prescription drug pricing issues, particularly related to MFN. Medicare Part B provisions relating to home infusion of IVIG.

Health Issues

Matters related to access of plasma derived products, FDA drug approval and monitoring agency changes. Matters affecting plasma donation and potential plasma shortages. Pharmacy Benefit Manager reform.

Bills named in this filing 1

H.R. 1
One Big Beautiful Bill Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.